Different doses or strenghts? [General Sta­tis­tics]

posted by kumarnaidu – Mumbai, India, 2013-11-22 06:34 (4187 d 04:41 ago) – Posting: # 11940
Views: 8,706

Dear Dr_Dan,
Thanks for your prompt reply.

❝ I guess in your case we are talking about comparative bioavailabilities and the test products are no pure generic formulations, right?

Yes you are right here we are talking about comparative bioavailability and the generic they have prepared with slight modifications. But in protocol they are not talking about bioavailability. They will use cohort 1 for identifying dose equiavlent to Reference and using that dose they will show bioequivalence in Cohort 2.

Kumar Naidu

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
128 visitors (0 registered, 128 guests [including 7 identified bots]).
Forum time: 12:15 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5